What is Neuraxis, Inc. (NRXS) stock price today?

Neuraxis, Inc. (NRXS) currently trades at $7.44 per share. The stock has a market capitalization of $93.54M and a P/E ratio of —x.

Is NRXS stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Neuraxis, Inc. has a Smart Value Score of 20/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is -20.40.

What is Neuraxis, Inc.'s revenue and earnings?

Neuraxis, Inc. has trailing twelve-month (TTM) revenue of $3.57M with profit margins of -218.60%. Earnings per share (EPS) is $-0.95.

Is Neuraxis, Inc. financially healthy?

Neuraxis, Inc.'s Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of -20.40 places it in the distress.

NRXS

Neuraxis, Inc.

NYSE MKT: NRXS · HEALTHCARE · BIOTECHNOLOGY

$7.44

-2.23% today

Updated 2026-04-29

Market cap

$93.54M

P/E ratio

—

P/S ratio

26.21x

EPS (TTM)

$-0.95

Dividend yield

—

52W range

$2 – $8

Volume

0.2M

Market cap

$93.54M

P/E ratio

—

P/S ratio

26.21x

EPS (TTM)

$-0.95

Dividend yield

—

52W range

$2 – $8

Volume

0.2M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

6.0

Growth

5.5

Quality

C+

2.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

-20.4

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$11.00

+47.85%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 27.20% QoQ

+ Debt/equity 0.21x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -20.40 — distress zone

- Thin margins at -218.60%

- Negative free cash flow $-1.94M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$2.68M	$2.46M	$2.69M	$3.57M	$3.57M
Net income	$-4.78M	$-14.63M	$-8.24M	$-7.80M	$-1.71M
EPS	—	—	—	—	$-0.95
Free cash flow	$-2.36M	$-6.77M	$-6.13M	$-6.46M	$-1.94M
Profit margin	-178.05%	-594.57%	-306.84%	-218.55%	-218.60%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
NRXS	$93.54M	20	6.0	2.0	5.0	5.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Neuraxis, Inc. trades at $7.44. Our Smart Value Score of 20/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -20.40, it sits in the distress. TTM revenue stands at $3.57M. with profit margins at -218.60%.

Frequently asked questions

What is Neuraxis, Inc.'s stock price?

Neuraxis, Inc. (NRXS) trades at $7.44.

Is Neuraxis, Inc. overvalued?

Smart Value Score 20/100 (Grade F, Strong Sell).

What is the price target of Neuraxis, Inc. (NRXS)?

The analyst target price is $11.00, representing +47.8% upside from the current price of $7.44.

What is Neuraxis, Inc.'s revenue?

TTM revenue is $3.57M.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

-20.40 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNYSE MKT

CurrencyUSD

neuraxis.com

Quick metrics

P/S ratio26.21x

ROE-285.40%

Beta1.89

50D MA$6.64

200D MA$4.01

Shares out0.01B

Float0.01B

Short ratio—

Avg volume0.2M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

NRXS vs LLY →NRXS vs JNJ →NRXS vs ABBV →Stock screener →